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CHAPTER ONE
OVERVIEW AND HYPOTHESES
Micro-RNAs, or miRNAs, are a class of non-coding RNAs that are single
stranded and act to post-transcriptionally regulate mRNA expression. The
biogenesis pathway of miRNAs and their role in suppressing translation through
mRNA cleavage have been well described; however, it is still unclear what
cellular signaling mechanisms regulate the degradation of mature miRNA.
Recently, E2, the primary circulating estrogen, has been shown, in vivo, to
differentially regulate neuronal miRNA expression in a brain region-specific
manner (Rao et al., 2013, Endocrinology). Specifically, miR-181a was
significantly increased upon estrogen treatment in the ventral and dorsal
hippocampus; however, miR-181a precursor and primary transcript levels
remained unchanged, suggesting that estrogen is not upregulating miR-181a
transcription, but rather, stabilizing the mature form (Rao et al., 2015,
Oncotarget). This led to the hypothesis that estrogen stabilizes miR-181a in
neurons by altering the pool of endogenous RNA and by recruiting coregulatory
proteins away from the degradation machinery.
The following specific aims were developed to test the proposed
hypothesis.
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1) Evaluate the dependence of estrogen-mediated stabilization of miR-181a
on the presence of endogenous RNA.
miRNAs can be stabilized upon base pairing to endogenous mRNA
targets (Rüegger et al., 2012, Biochemical Sciences). Based on the
understanding that estrogen activates a variety of intracellular signaling pathways
affecting transcription, I predicted that the estrogen-mediated stabilization of miR181a will be abolished upon degrading endogenous RNA with micrococcal
nuclease.
2) Identify the role of the coregulatory protein PNRC2 in miRNA
degradation.
PNRC2 (proline-rich nuclear receptor coregulatory protein 2) has been
shown to interact with estrogen receptors (ERs) in a ligand-dependent manner to
promote transcription (Zhou et al., 2006, Nucleic Acids Research). However,
PNRC2 also has a distinct role in mRNA degradation; it binds to and activates
mRNA-decapping enzymes such as DCP1 (Lai et al., 2012, Structure).
Interestingly, in Caenorhabditis elegans, the decapping scavenger enzyme DCS1, an analog of DCP1, was found to be crucial for exoribonuclease 1 (XRN-1)
activity in the degradation of miRNAs (Meziane et al., 2013, Cell Cycle).
Therefore, I predicted that upon estrogen treatment, there would be increased
association of PNRC with ERs, and a corresponding decrease in the association
of PNRC and DCP1a, which subsequently leads to a decrease in XRN-1
recruitment and miRNA stabilization.

CHAPTER TWO
LITERATURE REVIEW
ESTROGEN SIGNALING PATHWAY
Estrogens are a class of steroid hormones that are essential for various
cellular processes such as proliferation, metabolism, and growth. 17β-estradiol
(E2), the predominant form of estrogen in the human body, is synthesized from
cholesterol after multiple enzymatic processing events. E2 can initiate cellular
signaling cascades by interacting with estrogen receptors, ERα and ERβ. The
binding of E2 to the receptor results in conformational changes that allow for ERα
and ERβ to dimerize. The dimerized receptors are then translocated to the
nucleus where they bind to estrogen response elements (ERE) to facilitate gene
expression (Marino et al., 2006, Curr. Gen.). Both homodimers and heterodimers
of ERα and ERβ can be formed upon ligand binding, and various combinations of
the dimer have been shown to differentially regulate transcription. There are also
multiple isoforms of ERα and ERβ resulting from splice variants, and these
isoforms further contribute to the complexity and diversity of estrogen mediated
gene transcription (Kampa et al., 2013, Hormones; Shults et al., 2015,
Endocrinology).
E2 can also trigger signaling cascades that have non-genomic effects.
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GPER1, a G-protein coupled receptor located in the endoplasmic reticulum, has
also been identified as a receptor for E2. Ligand binding dissociates the tripartite
G protein subunits in the intraluminal space of the endoplasmic reticulum. This
results in the activation of adenylyl cyclase activity, and cyclic adenosine
monophosphate (cAMP) levels are consequently increased. G protein activation
can also lead to intracellular calcium mobilization, activation of a variety of kinase
cascades, and regulation of monovalent ion channels (Prossnitz et al., 2008,
Physiology). In the context of the brain, these signaling pathways initiated by E2
can ultimately lead to neuroprotection, neurogenesis, and increased
neurotransmission (Arevalo et al., 2015, Nat Rev Neurosci).
The complexity of E2 signaling is particularly important for human health
as it is known to cause neuroprotective and cardioprotective effects in premenopausal women. However, following the menopausal transition and loss of
circulating 17β-estradiol, there are differential effects of this hormone in various
tissues. Estrogen replacement therapy can cause proliferation of breast and
uterine cancer, increase the risk of cardiovascular disease, and lead to neuronal
cell loss (Prentice et al., 2006, Epub). It remains unknown how the effects of E2
are modified in such diverse and cell-specific ways.
miRNA BIOGENESIS
miRNAs are a subfamily of noncoding RNAs that post-transcriptionally
regulate gene expression. The mature miRNA, between 20 and 24 nucleotides in
length, binds to complementary sequences in the 3’ UTR of target mRNAs to
either cause endonucleolytic cleavage or to repress translation. Endonucleolytic
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cleavage of the target mRNA is frequently observed in plants whereas
translational repression of the target mRNA seems to be the predominant mode
of regulation in metazoans (Ameres et al., 2013, Nature).
miRNAs are transcribed in the nucleus by RNA polymerase II (RNA Pol
II) into long primary miRNAs (pri-miRNA), which typically contain a stem loop
region, a 5’ cap, and a 3’ poly-A tail. Pri-miRNAs are generally transcribed
independently through their own promoter interactions with the canonical
transcriptional machinery; however, some miRNAs arise from the introns of
protein coding genes. Once transcribed, pri-miRNAs are processed by the
microprocessor complex which consists of the endonuclease Drosha and a
cofactor called DiGeorge Syndrome Critical Region 8 (DGCR8) (Gregory et al.,
2004 Nature). DGCR8 is critical for pri-miRNA recognition by Drosha (Han et al.,
2004 Genes Dev). The C-terminus of DGCR8 contains a protein-protein
interaction domain which allows it to bind to Drosha and two double-stranded
RNA binding domains (dsRBD) which recognize and interact with pri-miRNAs
(Denli et al., 2004, Nature). Drosha is a nuclear endonuclease specific for
double-stranded RNA sequences. It contains two RNase III domains (RIIIDs) that
sequentially cleave the 5’ lower stem and the 3’ overhang of the pri-miRNA.
Once the recognition and cleavage of the pri-miRNA is complete, the resulting
structure is precursor miRNA, or pre-miRNA. Pre-miRNA is then transported to
the cytoplasm by exportin 5 which forms a complex with Ran, a Ras related
GTPase (Yi et al., 2003, Genes Dev).
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Once in the cytoplasm, the pre-miRNA is then cleaved once more by
another RNase III enzyme called Dicer. Dicer has an N-terminal helicase domain
that interacts with the stem loop of the pre-miRNA to facilitate recognition
(Ketting et al., 2001, Genes Dev). Similarly, the PAZ (Piwi-Ago-ZWILLE) domain
facilitates the recognition and binding of the terminal ends of the pre-miRNA
(Macrae et al., 2006, Science). Once the precursor is successfully bound,
tandem RIIIDs of Dicer cleave the stem loop region producing a miRNA-miRNA*
duplex which consists of approximately 45 nucleotides.
This duplex is then loaded onto an argonaute protein (AGO) via an ATPdependent process, and RISC, or RNA induced silencing complex, is
subsequently assembled. Four different AGO proteins (AGO 1-4) exist, but only
AGO2 contains an active site on its PIWI domain that can endonucleolytically
cleave the target mRNA (Huntzinger et al., 2011, Nature Rev. Genet.). Following
the loading of the miRNA duplex, unwinding occurs where the passenger strand
(miRNA*) is quickly removed and degraded. The resulting single stranded
sequence is termed the guide strand. In rare instances, AGO2 can cleave the
passenger strand, and the remnants are subsequently removed by the
endonuclease C3PO (Liu et al., 2009, Science). Typically, however, the duplex is
unwound first, and degradation of the passenger strand occurs after its removal.
The selection of the guide strand is determined by a set of specific, yet
flexible, criteria. For instance, the strand with the more thermodynamically
unstable 5’ terminus is generally selected as the guide strand (Khvorova et al.,
2003, Cell). In addition, there is a preference for uracil to be in the first nucleotide
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position when determining the guide strand (Kawamata et al., 2009, Nature).
However, the criteria for guide strand selection are not necessarily absolute;
there are instances where the unfavorable strand is chosen as the guide strand.
Since the passenger strand is degraded quickly upon its removal, the relative
abundance of the passenger strand is significantly lower compared to the guide
strand. The lower relative abundance, however, does not exclude the passenger
strand of its mRNA silencing function. While comparatively less potent in its
silencing capabilities, the passenger strand can still be involved in mRNA
regulation (Chiang et al., 2010, Genes Dev).
Once the guide strand is determined, RISC facilitates the interaction of a
seed sequence on the 5’ end of the guide strand to its complementary mRNA
sequence. The seed sequence is only about 6 to 8 nucleotides in length and can
therefore base pair with hundreds of complementary mRNA targets. While
complementary base pairing can occur along all regions of the mRNA target,
silencing activity is mostly observed when the seed sequence binds to the target
3’ UTR (Bartel et al., 2009, Cell).
There are also other non-canonical pathways of miRNA biogenesis. For
example, the pri-miRNA cleavage step by the microprocessor complex can be
bypassed. mirtrons, or miRNAs located within introns, are formed directly from
mRNA splicing. The branched mirtron is then converted into a precursor-like
structure by the Lariat debranching enzyme (DBR1) (Babiarz et al., 2008, Genes
Dev). Likewise, processing of the precursor miRNA by Dicer can also be
circumvented. For example, pre-miR-451 is directly loaded onto RISC as its
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nucleotide sequence is too short to be recognized by Dicer. Once loaded, premiR-451 is trimmed by ribonucleases to facilitate its maturation (Cheloufi et al.,
2010, Nature).
In addition to these non-canonical pathways, there are still other
processes that can introduce variations to miRNA biogenesis and development.
For instance, isomirs, or miRNA isoforms, exhibit sequence heterogeneity
introduced not only by imprecise cleavage, but also by the addition of
nucleotides. Dicer, for example, can cleave the precursor form at varying sites
resulting in a diverse array of duplexes with different seed nucleotide
arrangements (Berezikov et al., 2011, Genome Res). As a consequence, these
differences in the 5’ end seed sequence can then alter the range of interactions
with potential mRNA targets.
The seed sequences can also be changed by the ADAR (adenosine
deaminase acting on RNA) enzyme. As its name suggests, ADAR facilitates the
conversion of adenosine to inosine. Interestingly, ADAR is primarily expressed in
neural tissue suggesting that miRNAs in the brain are more frequently edited
compared to other tissues (Hundley et al., 2010, Trends Biochem.). In
Drosophila, mature miRNAs can also be trimmed from the 3’ end by an enzyme
called Nibbler (Liu et al., 2011, Curr. Bio.). Similarly in humans, a Nibbler-like
exoribonuclease trims the 3’ end of mature miRNAs to alter its sequence (Han et
al., 2011, Curr. Bio.). The function of 3’ end trimming is not entirely understood,
since the seed sequence which is important for target binding is located in the 5’
end. However, it has been proposed that 3’ end trimming could alter the
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degradation kinetics of the mature miRNA and thereby the duration of target
mRNA repression. Finally, 3’ heterogeneity can also arise from the addition of
nucleotides to the 3’ end by TNTases, or terminal nucleotidyl transferases
(Rissland et al., 2007, Mol. Cell Bio.). This 3’ tailing process, especially
uridylation and polyadenylation, seems to be important for miRNA turnover.
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Figure 1. miRNA biogenesis pathway
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REGULATION OF miRNA BIOGENESIS
Every step of the miRNA biogenesis pathway can be regulated. As with
coding RNA, transcription of miRNA is initiated by various transcription factors
interacting with the promotor region. Multiple miRNAs can be transcribed from
the same promotor; these miRNAs form a miRNA cluster (Lee et al., 2002,
EMBO). MYC and p53, transcription factors important for mRNA transcription,
can also drive the transcription of miRNA clusters. However, there seems to be
specificity of MYC and p53 for particular miRNAs, as binding to some promotor
regions induce activation while others induce repression. For example, MYC
activates the miR-17 cluster, but generally inhibits the transcription of the miR15a cluster (Krol et al., 2010, Nature). Finally, miRNA transcription can also be
regulated by epigenetic means, namely DNA methylation and histone
modification (Davis-Dusenbery et al., 2010, J. Biochem.).
miRNA biogenesis can also be regulated at the microprocessor step.
Since the Drosha:DGCR8 complex is critical for pri-miR cleavage to the
precursor form, regulation of this complex can lead to profound changes in
miRNA abundance (Han et al., 2009, Cell). Interestingly, a form of self-regulation
exists between Drosha and DGCR8. DGCR8 stabilizes Drosha allowing for a
higher efficiency in the cleavage for Drosha targets. However, DGCR8 mRNA is
one of the many Drosha targets. DGCR8 mRNA cleavage by Drosha leads to its
destabilization, and DGCR8 translation is subsequently diminished.
Consequently, less DGCR8 protein is available to bind and stabilize Drosha, and
this, in turn, decreases Drosha activity (Yeom et al., 2006, Nucleic Acids Res.).
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There are also various post-translational modifications of Drosha that
can regulate its localization and function. For example, GSK3β, or glycogen
synthase kinase 3β, phosphorylates Drosha, and this particular modification is
required for its nuclear localization (Tang et al., 2010, Nucleic Acids Res).
Drosha can also be stabilized when acetylated or when bound to TDP43, or TAR
DNA-binding protein 43 (Di Carlo et al., 2013, Mol. Neurobiol.). Similarly, DGCR8
can also be post-translationally modified. For example, ERK can phosphorylate
DGCR8 to promote its stability, and HDAC1, or histone deacetylase 1, can
deacetylate DGCR8 to increase its binding affinity to pri-miRNAs (Herbert et al.,
2013, Cell Rep.). Finally, recent studies have shown that phosphorylated
MECP2, or methyl-CpG-binding protein 2, can bind to and sequester DGCR8
inhibiting its association with Drosha (Cheng et al., 2014, Dev. Cell).
The efficiency of Drosha processing can also be regulated by RNAbinding proteins such as p68 and p72. Intermediate protein interactions can
stimulate Drosha processing such as the SMAD and p53 interaction with p68
(Davis et al., 2008, Nature). Other RNA-binding proteins, such as KSRP and
HNRNPA1, can also bind to the terminal loop of pri-miRNAs to further facilitate
Drosha mediated cleavage (Trabucchi et al., 2009, Nature). Dicer processing can
also be regulated by RNA-binding proteins. KSRP (KH-type splicing regulatory
protein), which is important in Drosha-mediated processing, can also stimulate
Dicer activity by binding to the terminal loop region of precursor miRNAs. In the
case of let-7 pre-miRNA, LIN28 can compete with KSRP for the terminal loop
binding site; therefore, with LIN28 bound, dicing of let-7 pre-miRNA is inhibited
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which ultimately leads to a decrease in mature let-7 abundance (Trabucchi et al.,
2009, Nature).
In Drosophila, Dicer interacts with two Loquacious (Loqs) isoforms: LoqsPA and Loqs-PB. Both Loqs-PA and Loqs-PB interact with Dicer through their
dsRBDs and are generally required for the processing of pre-miRNA
(Forstemann et al., 2005, PLoS). In contrast, human Dicer binds to two known
dsRBD proteins: TRBP (TAR RNA-binding protein) and PRKRA (protein kinase
interferon-inducible double stranded RNA dependent activator) (Garcia et al.,
2007, Biochimie). TRBP, in turn, can be stabilized by ERK phosphorylation which
then can improve the duration and efficiency of Dicer processing (Paroo et al.,
2009, Cell).
Finally, miRNA biogenesis can also be regulated by post-translationally
modifying AGO proteins at the level of RISC assembly. C-P4H(I), or type I
collagen prolyl-hydroxylase, is thought to stabilize AGO2 through hydroxylation
(Wu et al., 2011, Mol. Cell. Biol.). MAPK phosphorylation of AGO2 at Serine 387
facilitates the localization of AGO2 to processing bodies where translational
repression of mRNA targets is thought to occur (Zeng et al., 2008, Biochem.).
However, when AGO2 is phosphorylated at Tyrosine 529, its ability to bind
miRNAs is significantly reduced (Rudel et al., 2011, Nucleic Acids Res).
Therefore, depending on the site of phosphorylation, AGO function can be
completely altered. AGO proteins can also be ubiquitinated by E3 ubiquitin
ligases to be targeted to the proteasome for degradation (Rybak et al., 2009,
Nature). The degradation of AGO proteins via the proteasome pathway could
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ultimately affect mature miRNA stability as more miRNAs would be unbound and
exposed to various exonucleases that are present in the cytoplasm.
miRNAS IN THE BRAIN
Distinct miRNAs have been found uniquely in brain tissue. For example,
miR-9 has been shown to be an important factor in neuronal differentiation
(Smirnova et al., 2005, Eur J Neurosci). Interestingly, miR-9 triggered the
differentiation of embryonic stem cells as well as neural stem cells into neurons
(Saunders et al., 2010, Aging). miR-7, on the other hand, was found to be
important for oligodendrocyte development and promoted myelination, while miR128 has been shown to be essential for synaptogenesis (Adlakha and Saini,
2014, Molecular Cancer).
miRNA dysregulation in the brain has also been linked to various
neurological disorders. Interestingly, a mutation in the DGCR8 enzyme was
found to significantly increase the risk for schizophrenia, suggesting that the
insufficient processing of pri-miRNAs was related to the diseased state (Stark et
al., 2008, Nature Genetics). Postmortem studies of brains from patients with
schizophrenia revealed a general decrease in miRNA expression, especially in
the prefrontal cortex which is critical for cognition and social behavior (Perkins et
al., 2007, Genome Biology).
In patients with Alzheimer’s disease, miRNAs targeting amyloid precursor
protein (APP) such as miR-106a and miR-106b are generally dysregulated
(Herbet et al., 2008, Acad Sci). Additionally, miR-9 levels decreased drastically
when primary neuron cultures were treated with ß-amyloid, suggesting that
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plaque formation inhibited neurogenesis and regeneration (Schonrock et al.,
2010, PLOS). In postmortem studies, miR-9 has been found to be consistently
downregulated in Alzheimer’s patient brains, whereas miR-125b is upregulated
(Cogswell et al., 2008, Journal of AD). While further research is needed to fully
understand the mechanism of how the dysregulation of these specific miRNAs
can lead to disease, their pattern of dysregulation offers promising potential as
biomarkers for various disease states.
ESTROGEN REGULATION OF miRNA
Interestingly, estrogen has been shown to regulate miRNA expression in
vivo. However, most of these studies have focused on E2’s effect on miRNA in
the context of breast cancer. In MCF-7 cells, a human breast cancer cell line,
estrogen decreased the expression of miR-206 (Adams et al., 2007, Mol
Endocrinology). Another study utilized microarrays to compare miRNA
expression in MCF-7 cells following estrogen treatment and found up to 38
miRNAs were differentially regulated by estrogen treatment (Pan et al., 2008, J
Cell Mol). Generally, widespread decreases in miRNA expression levels have
been reported upon estrogen treatment in various breast cancer cell lines (Maillot
et al., 2009, Endocrinology).
However, there have been several miRNAs that have been identified to be
upregulated with E2 treatment. Specifically, Bhat-Nakshatri and colleagues found
that miR-let-7f and miR-98 showed robust increases of up to a 3-fold difference
following estrogen treatment. Interestingly, previous studies showed that E2 also
mediated the increased transcription of MYC and E2F2 mRNA, which are
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putative mRNA targets for miR-let-7f and miR-98. Knockdown of miR-let-7f and
miR-98 confirmed this target interaction, supporting the notion that miR-let-7f and
miR-98 act to counterbalance E2-mediated increases in c-Myc and E2F2 to
maintain homeostasis (Bhat-Nakshatri et al., 2009, Nucleic Acids Research).
Additionally, Chromatin ImmunoPreceipitation (ChIP) assays were used to
determine that miR-21 had a regulatory region responsive to ERα, suggesting
that E2 can directly upregulate pri-miR-21 transcription. Interestingly, it has also
been shown that Dicer mRNA can be upregulated through ERα-mediated
transcription, potentially introducing an additional layer of complexity involving
pre-miRNA processing leading, ultimately, to alterations in miRNA abundance
(Bhat-Nakshatri et al., 2009, Nucleic Acids Research). Furthermore, miR-222,
miR-221, and miR-29a levels were significantly increased in ERα negative breast
cancer cells. This finding was interesting, because these miRNAs were shown to
repress Dicer levels by binding to the 3’ UTR of Dicer1 mRNA. These results
taken together provide even more clarity as to why ERα negative breast cancer
cells express low levels of Dicer (Cochrane et al., 2010, Horm Cancer).
Furthermore, some specific miRNAs, such as miR-22, have been shown
to directly target the 3’ UTR of ERα mRNA to inhibit its translation. Consequently,
the overexpression of miR-22 resulted in the inhibition of ERα levels and thereby
reduced ERα mediated estrogen signaling pathways (Pandey et al., 2009,
Molecular and Cellular Biology). Therefore, it can be reasonably inferred that the
estrogen signaling pathway and the miRNA biogenesis pathway seem to be
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intricately intertwined at various intersections—each pathway having the ability to
regulate the other.
Unfortunately, there have been few studies that have investigated
estrogen regulation of miRNA expression in a context removed from breast
cancer research. Recently, estrogen has been shown, in vivo, to differentially
regulate neuronal miRNA expression in a brain region-specific manner (Rao et
al., 2013, Endocrinology). In this study, microarray analysis revealed that 34
miRNAs were significantly regulated by estrogen treatment in the ventral
hippocampus. Interestingly, E2 had no effect on the processing steps of miRNA
biogenesis. The steady state levels of Drosha, Dicer, and AGO2 were not altered
with estrogen treatment, suggesting that changes in miRNA levels could be due
to E2 acting directly at the promotor level by interacting with estrogen receptors
to potentiate pri-miRNA transcription. The other intriguing possibility for the
changes in miRNA expression levels could be further downstream—where the
stability of mature miRNAs is regulated by E2.
miRNA DEGRADATION
Recent research on miRNA stability has primarily involved identifying key
enzymes that are part of the degradation process in both plants and animals.
Certain candidate nucleases, such as small RNA degrading nucleases (SDNs)
have been proposed to degrade miRNAs in Arabidopsis thaliana from the 3’-to-5’
direction (Ramachandran et al., 2008, Science). In Caenorhabditis elegans and
in humans, the 5’-to-3’ exoribonuclease XRN-1, is critical for miRNA degradation
(Chatterjee et al., 2011, Dev. Cell). Recently, it has been revealed that a critical
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enzyme in miRNA degradation is the decapping scavenger protein DCS-1. This
finding was interesting due to the fact that mature miRNAs, unlike mRNAs, do
not have a 5’ cap. DCS-1 was important for another reason—it recruited XRN1,
an exoribonuclease, to the miRNA to initiate 5’ to 3’ degradation (Bosse et al.,
2013, Molecular Cell). Therefore, the vast array of unique enzymes found to be
important for miRNA degradation seem to oppose the notion of a general, widely
conserved pathway for miRNA degradation; rather, different organisms seem to
rely on distinct mechanisms of degradation.
Generally, it has been observed that miRNAs are globally more stable
than mRNA (Gantier et al., 2011, Nucleic Acids Res). In addition, highly
expressed miRNAs are correlated with a higher rate of turnover whereas lowly
expressed miRNAs seem to be relatively more stable. miRNA turnover kinetics
also varied with cell type, affirming the hypothesis that miRNA stability is context
dependent (Li et al., 2013, BioMed Research Int.).
The specific triggers that regulate the miRNA degradation process is,
however, still unclear. One intriguing possibility is that miRNA turnover is
mediated by its mRNA target. While mRNAs are generally thought to be
translationally repressed or cleaved by interacting with mature miRNAs loaded
unto RISC, there have been studies that suggest a reciprocal means of
regulation where miRNA stability can be influenced by mRNA as well. For
instance, in HEK293T cells, miRNAs were degraded more rapidly upon base
pairing with highly complementary mRNA targets compared to pairing with
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mRNA targets with less than 8 nucleotide lengths of complementarity (Ameres et
al., 2010, Science).
Cell cycle progression has also been observed as a regulator of miRNA
stability. Specific cellular environments are thought to accelerate miRNA
degradation, especially during cell cycle transitional phases. A proposed
mechanism of miRNA degradation driving cell cycle progression closely mirrors
the rapid induction and turnover of various cyclins which activate CDKs, or cyclin
dependent kinases, to initiate a signaling cascade specific to the phase of the cell
cycle. For instance, miR-29b was found to be enriched in mitotic cells. The halflife of miR-29b was greater than 12 hours in mitotic cells compared to
approximately 4 hours in non-dividing cells (Hwang et al., 2007, Science). Some
miRNAs are expressed constitutively at almost undetectable levels so that its
activity can be quickly abolished when necessary. An example of this is miR-503
which was observed in growth arrested cells but became undetectable upon reentry to the cell cycle (Rissland et al., 2011, Mol. Cell). This finding was intuitive,
as the factors important for cell cycle progression, cyclin D1, cyclin E1, and
CDK6, were all found to be putative targets for miR-503.
Recently, there have been some interesting studies investigating the
possibility of miRNA turnover regulated by extracellular signals. For example,
EGF (epidermal growth factor) treatment rapidly decreased levels of 23 miRNAs
in MCF10A breast epithelial cells (Avraham et al., 2010, Sci. Signal). Common
targets of these miRNAs included immediate early genes and other growth
promoting genes. These findings suggest that EGF-mediated proliferation is
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activated partly by the rapid turnover of several growth-inhibiting miRNAs. These
studies, unfortunately, failed to differentiate between miRNA degradation and
repression of their expression.
Rapid turnover, however, seems to be a prevailing feature of miRNAs in
neurons. One study examined miRNA turnover in embryonic stem cells in
relation to differentiated pyramidal neurons and found rapid miRNA turnover in
pyramidal neurons but not in the undifferentiated state (Krol et al., 2010, Cell).
miRNAs taken from primary human neuronal cultures and from post-mortem
brain tissues also exhibited significantly shorter half-lives of less than three and a
half hours, as compared to those reported in other non-differentiated cells (Sethi
et al., 2009, Neuroscience Letters).
This rapid turnover in neurons seems to be dependent on neuronal
activity. When tetrodotoxin was used to block action potential formation, the rapid
degradation of most miRNAs was prevented. The major exception to this rule
was miR-132 which experienced rapid decay when glutamate receptors were
experimentally blocked (Krol et al., 2010, Cell). Otherwise, a positive correlation
between neuronal activity and rapid miRNA decay was observed. Another study
reported that XRN-2 and PAPD4—an exoribonuclease and a poly-A polymerase
important for miRNA degradation—were expressed weakly in immature neurons,
but levels seemed to accumulate as maturation occurred. Interestingly, XRN-2
and PAPD4 levels were virtually nonexistent in glial and endothelial cells,
supporting the notion that neurons are distinct in their characteristic of having
higher rates of miRNA degradation (Kinjo et al., 2013, Exp. Neurology).
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Post-transcriptional modifications to the miRNA are another way stability
can be regulated. In HEK293 cells, knockdown of the m6A demethylase, FTO,
resulted in the steady state level change of 17 miRNAs, implying that methylation
of adenosine could be important in determining the stability of a subset of
miRNAs (Berulava et al., 2015, PLOS). In plants, the 3’ end of miRNAs is
methylated by the methyltransferase HEN1. This methylation offers effective,
albeit incomplete, protection from being degraded by small RNA degrading
nucleases (SDNs) (Li et al., 2005, Curr. Biol.).
Oligouridylation, where 10 to 30 nucleotides are added to the 3’ end of the
miRNA by the terminal nucleotidyl transferase HESO1, accelerated miRNA
degradation by SDNs, suggesting that uridylation either promoted the assembly
of the degradation machinery or provided the fully formed machinery with a more
preferable docking site (Zhao et al., 2012, RNA Biol). A similar effect of instability
mediated by uridylation can be seen in Chlamydomonas reinhardtii where a
different terminal nucleotidyl transferase called MUT68 is responsible for
uridylating the 3’ ends of miRNAs. Unsurprisingly, this uridylation promoted
degradation of the miRNA by RRP6, or ribosomal RNA processing protein 6
(Ibrahim et al., 2010, Proc. Natl. Acad. Sci.). For human miRNAs, however, a
different effect was seen upon uridylation. The nucleotidyl transferase TUTase 4
was found to uridylate miR-26a in human lung alveolar epithelial cells. However,
uridylation did not affect miR-26 degradation kinetics; rather, there was a
reduction in the efficacy of miR-26a’s inhibitory effects on its target interleukin-6
(Jones et al., 2009, Nat Cell Bio). To add another layer of complexity, precursor
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miRNAs were shown to be uridylated as well, and depending on the specific
context of uridylation, the effects of uridylation were vastly different.
Oligouridylation of the pre-miRNA by TUT4 inhibited miRNA biogenesis whereas
monouridylation seemed to promote miRNA biogenesis. Interestingly, when the
3’ end of the precursor was trimmed by a nuclease prior to uridylation by TUT4,
the pre-miRNA was more prone to degradation (Kim et al., 2015, EMBO).
Therefore, the consequences of uridylation on miRNA stability seem to be
heavily dependent on both species and context.
While polyadenylation has not been studied as extensively as uridylation
with respect to miRNA turnover, post-transcriptional modifications involving
polyadenylation seem to also be context dependent. miR-122, expressed in
hepatocytes, was stabilized upon adenylation; however, adenylation of miRNAs
by the virally encoded VP55 protein resulted in rapid decay (Katoh et al., 2009,
Genes Dev.).
Recent research has also illuminated the ability of viruses to employ an
interesting method to destabilize host miRNAs. For instance, Herpesvirus saimiri
can encode several non-coding RNAs that can base pair with miR-27a.
Specifically, HSUR1 (Herpesvirus saimiri U RNA) was found to interact with the
seed sequence of miR-27a to promote its degradation (Cazalla et al., 2010,
Science). This intriguing finding sheds light on how specific miRNAs can be
targeted for degradation to elicit a preferred cellular response—namely, the
apparent viral inhibition of a host cell’s defense system.
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These previous studies have revealed various mechanisms by which
miRNA stability can be regulated. Both the biogenesis and degradation of many
miRNAs can be specifically targeted, and its effects seem to rely heavily on the
context of the cellular and physiological environment. As the field of miRNA
research moves forward, the mechanisms of regulation and extracellular cues
that negate or potentiate miRNA degradation must be better elucidated. The
present study investigated the role of E2 in the miRNA degradation process and
introduced hormonal triggers that can elicit differential effects on the turnover
process of specific miRNAs and the mechanisms that underlie this process.

CHAPTER THREE
THE ROLE OF ENDOGENOUS RNA
IN THE E2-MEDIATED STABILIZATION OF MIR-181A
INTRODUCTION
The role of endogenously expressed RNAs in mediating miRNA stability
has come under investigation in recent years. Single stranded, mature miRNAs
are generally thought to be stabilized by binding to their mRNA targets
(Chatterjee et al., 2011, Dev Cell). While the reason behind target-induced
stability of miRNAs is not fully known, it has been hypothesized that association
with RISC shields the mature miRNA from various exoribonucleases. Since base
pairing interactions between miRNA and target mRNA only occur after the
mature strand is loaded onto RISC, a case can be made that an abundance of
the target mRNA leads to a change in kinetics where the mature miRNA strand is
bound and thereby protected by RISC for a longer period of time. However, this
hypothesis has yet to be confirmed. Moreover, the factors that facilitate or initiate
the unloading process of the mature miRNA strand from RISC are still unknown.
Interestingly, mRNA targets that have a high degree of complementarity
to the mature miRNA sequence destabilize the corresponding miRNA.
Specifically for miR-223 in HEK293T cells, a significantly faster rate of
degradation was observed when the mature form was incubated with a perfectly
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complementary sequence as compared to a sequence that had a two nucleotide
bulge in the center (Baccarini et al., 2011, Curr Bio).
Antagomirs, or synthetically produced miRNA silencing agents, were
developed largely based on this notion of complementarity-induced miRNA
degradation. Antagomirs are highly complementary oligonucleotide sequences
that contain 2’-O-methylations in the sugar-phosphorothioate backbone along
with a cholesterol moiety conjugated to the 3’ end. These modifications protect
the single stranded antagomir itself from endogenous nucleases while still giving
it the ability to bind and initiate the degradation of its target miRNA (Krützfeldt et
al., 2007, Nucleic Acids Res).
This reciprocal modulation of miRNA by target RNA sequences is also
observed in neurons; highly complementary mRNA targets were found to trigger
the addition of single nucleotides to the 3’ end of the mature miRNA which
ultimately lead to 3’-to-5’ degradation by endogenous exoribonucleases (M de la
Mata et al., 2015, EMBO Rep). Therefore, it can be seen from the literature that
endogenous mRNA targets and even synthetically produced oligonucleotide
sequences can have profound effects on miRNA stability.
These studies aimed to determine if the presence of endogenous RNA
was necessary for the estrogen-mediated stabilization of miR-181a. My
hypothesis was that estrogen-mediated stabilization of miR-181a will be
abolished in the absence of endogenous RNA. I tested my hypothesis by using a
modified version of an in vitro miRNA turnover assay described by Chatterjee et
al (2009, Nature).
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APPROACH
To first confirm that E2 stabilized miR-181a in vitro, IVB cells, derived from
rat hypothalamus, were treated with DRB to inhibit transcription. Transcription
was inhibited to ensure that E2 could not alter mature mir-181a levels by
upregulating transcription. After DRB treatment, IVB cells were incubated with E2
or vehicle for 2 hours to determine the effect of treatment on mature miR-181a.
A miRNA degradation assay was performed as described by Chatterjee et
al to visualize the degradation of a radiolabeled, mature miR-181a transcript
through time. Since the mature form of the miRNA was added into the system
exogenously, any effect of E2 observed for miR-181a was assumed to be on the
mature form. The miRNA degradation assay was then repeated with a
radiolabeled, mature miR-124 construct to determine if the stabilizing effect of E2
was miRNA specific.
Finally, to determine the role of endogenous RNA on the E2-mediated
stabilization of miR-181a, a modified form of the miRNA degradation assay was
used. Briefly, IVB cells were treated with either E2 or vehicle treatment for 48
hours and then lysed with a mild non-denaturing lysis buffer. Lysates were
treated with micrococcal nuclease in order to degrade all nucleotide sequences
that were present endogenously. There were two different treatment groups:
control (vehicle or estradiol treated IVB cells with EGTA only) and MNase
(vehicle or estradiol treated IVB cells with MNase and EGTA). After performing
the miRNA degradation assay, the levels of radiolabeled miR-181a were
determined at each time point by using densitometry through ImageJ software.
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The fold change of miR-181a levels from each time point compared to T0 was
determined, and a Student’s t-test was used to discover significant differences in
the fold change of miR-181a levels.
RESULTS
The first experiment aimed to determine the effect of E2 on mature miR181a levels in rat hypothalamic neurons (IVB). The results showed that E2
treatment increased mature miR-181a levels (Fig. 2a). Similarly, E2 treatment
increased miR-181a levels in the presence of a transcriptional inhibitor, DRB
(Fig. 2b). These data suggest that the observed E2-induced increases in mature
miR-181a were not due to increases in the primary miR-181a transcript.
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Figure 2. E2 stabilizes miR-181a in vitro (A) RT-qPCR results showing relative
expression of miR-181a levels between E2-treated and vehicle-treated IVB cells.
(B) RT-qPCR results showing fold change in miR-181a levels between E2treated and vehicle-treated IVB cells following DRB treatment. Two sample t-test
was performed to test for significance. * indicates p < .05 (n=3)
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Next, I used a miRNA degradation assay to determine if E2 treatment
increased mature miR-181a stability. As shown in Figure 3a, E2 treatment
prolonged the levels of mature 32PmiR-181a for 120 minutes, whereas the
expression was significantly reduced after 60 minutes in vehicle-treated cells.
Notably, the appearance of

32PmiR-181a

degradation products coincided with the

disappearance of the mature miRNA (Fig. 3a). Quantitative analysis of 3
independent experiments revealed a statistically significant difference between
vehicle and E2 treatment after 120 minutes when the densitometry values were
normalized to time zero (T0) (Fig. 3b).
To determine if this stabilizing effect of E2 was specific to miR-181a, I
repeated the degradation assay using a radiolabeled nucleotide sequence for
miR-124. miR-124 was chosen because it is highly expressed in the rat brain,
and is not altered by E2 treatment in vivo (Rao et al., 2013, Endocrinology). As
predicted, the stabilizing effect of E2 treatment was no longer observed in the
case of 32PmiR-124. 32PmiR-124 was present throughout all 5 time points for both
treatment groups displaying a longer half-life compared to miR-181a (Fig 4a).
Interestingly, E2 treatment even seemed to accelerate 32PmiR-124 degradation.
At the 240-minute time point, there was a significant decrease in 32PmiR-124
radioactivity with E2 treatment, as determined by the densitometry values relative
to T0 (Fig. 4b). Therefore, not only was the stabilizing effect of E2 specific to
miR-181a, a destabilizing effect was observed when another miRNA was tested.
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Figure 3. E2-mediated stabilization of miR-181a through time (A) 0, 15, 60,
120, and 240 represent length of time in minutes of radiolabeled miR-181a
incubation with lysate. The first 5 time points represent the vehicle treated IVB
cells, and the following 5 time points represent the estrogen treated IVB cells. (B)
The bar graph depicts densitometry values relative to T0 of radiolabeled miR181a with E2 or vehicle treatment through time. (N=3) Two sample t-test was
performed to examine differences at each time point. * indicates p < .05
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Figure 4. E2-mediated destabilization of miR-124 through time (A) 0, 15, 60,
120, and 240 represent length of time in minutes of radiolabeled miR-124
incubation with lysate. The first 5 time points represent the vehicle treated IVB
cells, and the following 5 time points represent the estrogen treated IVB cells. (B)
The bar graph depicts densitometry values relative to T0 of radiolabeled miR-124
with E2 or vehicle treatment through time. (N=3) Two sample t-test was
performed to examine differences at each time point. * indicates p < .05
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The next experiment aimed to determine whether the observed E2mediated stabilization of miR-181a was dependent on the endogenous pool of
RNA in the cell lysate. Therefore, cell lysate was first treated with micrococcal
nuclease to deplete all endogenous RNA. The nuclease reaction was quenched
and 32PmiR-181a oligonucleotides were incubated with the lysate according to the
previously described miRNA degradation assay protocol. With the endogenous
pool of RNA completely depleted from the system, the stabilizing effect of

32PmiR-

181a was no longer observed at the 120 minute time point (Fig. 5a). Instead,
32PmiR-181a

expression levels were stable throughout all 5 timepoints

independent of vehicle or E2 treatment (Fig. 5b). This suggested that the
stabilizing effect of E2 on 32PmiR-181a was at least partly mediated by the
endogenous pool of RNA since this effect was no longer seen after depleting the
system of all RNA.
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Figure 5. E2-mediated stabilization of miR-181a is abolished with MNase
treatment (A) 0, 15, 60, 120, and 240 represent length of time in minutes of
radiolabeled miR-181a incubation with lysate. The first 5 time points represent
the vehicle treated IVB cells, and the following 5 time points represent the
estrogen treated IVB cells.(B) The bar graph depicts densitometry values relative
to T0 of radiolabeled miR-181a with E2 or vehicle treatment through time. (N=3)
Two sample t-test was performed to examine differences at each time point. *
indicates p < .05
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DISCUSSION
Overall, these studies revealed the novel finding that E2 treatment can
differentially affect the degradation kinetics of specific miRNAs in the rat brain.
Previous data from our lab suggested that E2 stabilized the mature miR-181a
transcript in the rat hypothalamus, since E2 significantly increased mature miR181a levels with no effect on the primary and precursor forms (Rao et al., 2015,
Oncotarget). These data suggested that the E2-mediated increase of miR-181a
was due to the stabilization of the mature form rather than upregulation of its
transcription. This hypothesis was supported by both the miRNA degradation
assay using radiolabeled, mature miR-181a (Fig. 3) and the in vitro studies
utilizing DRB (Fig. 2b).
Interestingly, a different effect of E2 treatment on miR-181a was
observed in MCF7 breast tumor cells by Maillot and colleagues. E2 treatment
was found to decrease both pri-miR-181a and mature miR-181a expression.
Additionally, treatment with the transcriptional inhibitor, actinomyocin D,
abolished the E2-mediated decrease of miR-181a, suggesting that E2
downregulated the transcription of miR-181a (Maillot et al., 2009, Cancer
Research). In bone marrow-derived mesenchymal stem cells, miR-181a levels
were similarly decreased with E2 treatment (Shao et al., 2015, FASEB).
Therefore, it seems that E2’s effect on the miRNA degradation process is not
only miRNA specific, but variable depending on the tissue and cellular
environment.
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The present findings also indicate that the stabilizing effect of E2 is
mediated through the pool of endogenous RNA. These results are consistent
with evidence supporting a role for mRNAs in the stabilization of mature miRNAs,
although our experimental paradigm precludes ruling out other RNA species
(Pasquinelli, 2012, Nature Reviews Genetics). Since E2 is a potent initiator of
signaling cascades that can lead to alterations in mRNA transcription, it is
conceivable that mRNA targets of miR-181a are upregulated resulting in more
target-mediated stabilization. This mode of action would explain the miRNAspecific effect of E2 that was observed. While E2 was stabilizing for miR-181a, it
destabilized miR-124. Mature miRNA transcripts have a short seed sequence
about 2 - 8 nucleotides in length which can provide a binding target for many
mRNAs. Therefore, target-mediated stabilization would explain how E2 could
have miRNA specific effects.
An alternate possibility is that endogenous RNAs actively destabilize
miRNAs, and the micrococcal nuclease degraded some of these destabilizing
effectors. However, this interpretation is not supported by evidence in the
literature. For example, only virally induced long noncoding RNAs and perfectly
complementary mRNA targets have been shown to be destabilizing to their
respective miRNAs (Baccarini et al., 2011, Curr Bio; Cazalla et al., 2010,
Science). The IVB cells used in these experiments, to our knowledge, were not
virally infected, and perfectly complementary mRNA targets are generally not
found in metazoans. However, this possibility cannot be ruled out by my
experimental design.
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Another interpretation for the stabilization of miR-181a via RNA depletion
is that there was increased incorporation of the radiolabeled 32PmiR-181a
construct into RISC. Since all RNAs were depleted with micrococcal nuclease
treatment, the custom radiolabeled

32PmiR-181a

would not be competing with

other endogenous miRNAs for RISC occupancy. If incorporation into RISC is
increased, Argonaute-bound miR-181a could be protected from exonucleases by
the assembly of proteins that comprise the complex.
The present findings supported my hypothesis that estrogen-mediated
stabilization of miR-181a will be abolished in the absence of endogenous RNA.
These findings suggest the importance of endogenous RNA in mediating the
stabilizing effect of E2 on mature miR-181a levels.

CHAPTER FOUR
THE ROLE OF PNRC2 IN THE E2-MEDIATED STABILIZATION OF MIR-181A
INTRODUCTION
There are multiple ways in which E2 can modulate intracellular signaling
processes. In the canonical mechanism of estrogen signaling, E2 binds to
estrogen receptors, ERα or ERβ. These receptors then dimerize and translocate
into the nucleus where they bind to EREs, or estrogen response elements, near
the promotor site of target genes. In essence, ERs act as transcription factors to
initiate gene expression. Like other transcription factors, ERs can bind to
coactivators which further help to facilitate transcription. PNRC2, or proline-rich
nuclear receptor coregulatory protein 2, is one family of coactivators that have
been shown to bind to estrogen receptors through its SH3-binding motif (Zhou et
al., 2006, Nucleic Acids Res).
Interestingly, PNRC2 also has a role in mRNA degradation. The unique
proline-rich region of PNRC2 has been shown to interact with the EVH1 domain
of Dcp1a (Lai et al., 2012, Structure). Dcp1a is a decapping enzyme that
removes the 5’ cap of mRNAs. After the 5’ cap is removed, the decapping
machinery can recruit XRN1, which subsequently degrades the mRNA from the
5’-to-3’ direction (Braun et al., 2012, Nature). Importantly, XRN1 is also
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responsible for the degradation miRNAs in C. elegans and in humans (Bail et al.,
2010, RNA).
Therefore, these studies aimed to directly link components of the
estrogen signaling pathway to miRNA degradation. I hypothesized that E2
treatment would increase the association of PNRC2 with ERs resulting in a
corresponding decrease its association with DCP1a. The dissociation of PNRC2
and DCP1a would subsequently decrease XRN-1 recruitment to mature miRNAs
leading to increased stabilization. This hypothesis was tested by using a
combination of approaches including immunocytochemistry and siRNA
knockdown of PNRC2. The results from these studies would provide a novel and
specific mechanism for E2-mediated stabilization of miRNAs.
APPROACH
Using the same in vitro E2 or vehicle treatment paradigm,
immunocytochemistry was performed to visualize differences in PNRC2
localization in IVB cells. After the cells were fixed, primary antibodies to PNRC2
and DCP1a were applied followed by the addition of secondary antibodies
conjugated to two different fluorophores. PNRC2 and DCP1a signals were then
detected through a fluorescence microscope. Finally, PNRC2’s nuclear and
cytoplasmic localization and its co-localization with DCP1a were then determined
using IMARIS.
To determine if PNRC2 has a functional role in miR-181a stabilization,
PNRC2 siRNA was transfected into IVB cells to knockdown its expression. To
ensure that any observed changes were due solely to miR-181a stability, IVB
cells were initially treated with DRB to inhibit transcription. Following DRB
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treatment, cells were incubated with either E2 or vehicle treatment for 2 hours.
After verification of PNRC knockdown using Western blotting techniques, RNA
was isolated from the various samples. miR-181a levels were then determined by
RT-qPCR, and the relative expression of miR-181a was normalized to 5s-rRNA,
which is stably expressed in various regions of the brain.
RESULTS
The aim of the first experiment was to determine whether E2 treatment
altered the expression or localization of PNRC2 in IVB cells. I hypothesized that
more PNRC2 would localize to the nucleus with E2 treatment, since PNRC2 can
function as a coactivator to the estrogen receptor-mediated transcription
machinery. However, IMARIS software analysis revealed that E2 treatment did
not alter the nuclear or cytoplasmic localization of PNRC2 (Fig. 6). Further, there
were no significant differences in the ratio of nuclear to cytoplasmic PNRC2 or in
the ratio of nuclear to total PNRC2 between the vehicle treated and E2 treated
IVB cells (Fig. 7). These effects were not dependent on changes in total PNRC2
content, as E2 treatment did not alter the levels of PNRC2. More importantly, the
expression levels of total nuclear and cytoplasmic PNRC2 proteins remained
unchanged between cells after E2 or vehicle treatment (Fig. 8).
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Figure 6. Immunostaining for PNRC2 after E2 treatment. PNRC2 localization
is marked by the green (FITC) signal whereas the nucleus is stained in blue
(DAPI). The secondary only group was not incubated with any primary antibody.
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Figure. 7. PNRC2 nuclear to cytoplasmic localization is unchanged with E2
treatment. (A) Ratio of nuclear to cytoplasmic PNRC2 puncta with vehicle or E2
treatment. (B) Ratio of nuclear to total PNRC2 puncta with vehicle or E2
treatment. (N=3) Two sample t-test was performed to test for significance. *
indicates p < .05
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cytoplasmic PNRC2 levels between E2 and vehicle treated cells.
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Next, I tested whether E2 altered the co-localization of PNRC2 with
DCP1a. I hypothesized that E2 treatment would decrease the association of
PNRC2 and DCP1a, since more PNRC2 would be bound to ERs in the presence
of E2. Co-localization anaylsis was performed using IMARIS. The max intensity
of the DCP1a signal was then analyzed for each PNRC2 puncta to evaluate the
level of co-localization between these two proteins. It was determined that a
DCP1a intensity max of 420 was the threshold in which the red DCP1a signal
was reliably seen to overlap with the green PNRC2 signal (Fig.10a). Therefore,
co-localization of PNRC2 and DCP1a was defined to be PNRC2 surfaces
exhibiting a DCP1a intensity max of over 420. When puncta with these specific
criteria were analyzed, it was determined that there was a significant decrease in
the co-localization of PNRC2 and DCP1a with E2 treatment (Fig.10b).
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Figure 9. Immunostaining for PNRC2 and DCP1a with E2 treatment. PNRC2
is shown in green (FITC), DCP1a is shown in red (Texas Red), and the nucleus
is stained in blue (DAPI). The secondary only group was not incubated with any
primary antibody.
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Figure 10. PNRC2 and DCP1a co-localization decreases with E2 treatment.
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In order to ensure that the DRB treatment was successfully inhibiting
transcription, I tested the levels of several immediate early genes following 2
hours of DRB treatment. I hypothesized that inhibiting transcription would
decrease the abundance of immediate early genes. As expected, RT-qPCR
results showed that C-Fos, C-Jun, and C-Myc levels were all decreased following
DRB treatment (Fig. 11). C-Fos and C-Myc levels were significantly decreased
compared to the control group, suggesting that the DRB treatment was
successfully inhibiting transcription (Fig. 11).
I then tested the efficacy of the PNRC2-siRNA to determine if PNRC2
protein abundance would decrease with siRNA transfection. As expected, the
IVB cells transfected with scrambled siRNA did not affect the protein levels of
PNRC2; however, the PNRC2 siRNA significantly knocked down PNRC2 levels
from the non-treated control group (Fig. 12). Densitometry analysis relative to ßactin revealed that there was about a 50% knockdown of PNRC2 protein levels
with the PNRC2 siRNA (Fig.12). These data indicate that the PNRC2 siRNA was
successfully able to knockdown PNRC2 expression.

47

1.8
1.6

Fold Change

1.4
1.2
1
0.8

*

0.6
0.4

*

0.2
0
control
C-Fos

DRB

control
C-Jun

DRB

control
C-Myc

DRB

Figure 11. DRB decreases the levels of immediate early genes. RT-qPCR
results showing differences in C-Fos, C-Jun, and C-Myc levels with DRB
treatment. (N=3) Two sample t-test was performed to test for significance. *
indicates p < .05
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Finally, to determine whether PNRC2 has a functional role in miR-181a
stabilization, I tested the hypothesis that knocking down PNRC2 protein levels
would abolish the E2 mediated stabilization of miR-181a. The results indicated
that E2 treatment increased miR-181a levels when transcription was inhibited
with DRB (Fig. 13a). However, when PNRC2 expression was knocked down, an
increase in miR-181a was no longer observed (Fig.13b). These findings suggest
that PNRC2 has an important role in the E2-mediated stabilization of miR-181a.
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Figure 13. The E2-mediated stabilization of miR-181a is abolished
withPNRC2 knockdown. (A) RT-qPCR results showing fold change in miR-181a
levels between estrogen-treated and vehicle-treated IVB cells following DRB
treatment. (B) RT-qPCR results showing fold change in miR-181a levels between
estrogen-treated and vehicle-treated IVB cells following siRNA mediated PNRC2
knockdown and DRB treatment (N=3). Two sample t-test was performed to test
for significance with * indicating p < .05.
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DISCUSSION
Overall, these studies revealed the novel finding that PNRC2 is required
for the E2-mediated stabilization of miR-181a. While previous research has
examined the role of PNRC2 in mRNA degradation (Lai et al., 2012, Structure),
there has not been any investigation, to our knowledge, into PNRC2’s role in
miRNA degradation. Furthermore, the present study found that E2 treatment
decreased PNRC2 co-localization to DCP1a, suggesting less downstream
activation of the degradation machinery. Lai et al. previously found that disrupting
this interaction of PNRC2 and DCP1a inhibited mRNA degradation (Lai et al.,
2012, Structure). While the present study did not directly investigate the
involvement of XRN-1, activated DCP1a has been shown to recruit XRN-1
through the scaffolding protein EDC4 (Enhancer of mRNA-decapping protein 4)
(Chang et al., 2014, Nucleic Acids Res.). Since XRN-1 has also been implicated
in miRNA degradation as well as mRNA degradation, it is conceivable that an
inhibition in XRN-1 recruitment due to a decrease in PNRC2-DCP1a colocalization leads to miRNA stabilization.
Interestingly, there was no difference in the ratio of nuclear to cytoplasmic

PNRC2 with E2 treatment, suggesting that PNRC2 is not shuttled back and forth
from the nucleus. Rather, there seems to be consistent levels of PNRC2 in the
nucleus and the cytoplasm that remain unchanged with E2 treatment (Fig. 7).
Previous immunostaining experiments showed that PNRC2 was primarily
localized to the nucleus with only a faint detection in the cytoplasm (Zhou et al.,
2000, Mol. Endo.). While our data did reveal more PNRC2 puncta in the nucleus

52

compared to the cytoplasm, more cytoplasmic PNRC2 was observed compared
to what was seen by Zhou et al. However, Zhou et al., used a different cell line
derived from African green monkey kidney tissue in their experiments (Cos-1),
and this could explain the differences that were observed.
Since E2 treatment did not decrease PNRC2 levels in the cytoplasm, it is
still unknown how E2 treatment decreased PNRC2 co-localization with DCP1a.
PNRC2 was not the limiting factor, and PNRC2 function was not altered by its
translocation into the nucleus in a E2-dependent manner. This suggests that
PNRC2’s role as a coactivator for estrogen receptors in the nucleus is
independent from its role in the decapping machinery. Therefore, there has to be
some other mechanism of E2 action that decreases the co-localization of PNRC2
and DCP1a.
One possible mechanism of E2 decreasing PNRC2 co-localization with
DCP1a is through an interaction with the MAPK signaling pathway. E2 has been
shown to induce Shc (Src-homology and collagen homology) phosphorylation
which promotes the binding of two Grb-2 (growth factor receptor bound protein 2)
adaptor proteins (Song et al., 2002, Mol. Endocrinology). Interestingly, PNRC2
has also been shown to interact with Grb2 to suppress nuclear receptormediated signaling pathways (Zhou et al., 2004, Oncogene). Therefore, if Grb2 is
recruited to the estrogen receptor in a E2-dependent manner following Shc
phosphorylation, this mobilization of Grb2 to Shc could provide binding
opportunities for PNRC2. In this scenario, PNRC2 would not be translocated into
the nucleus upon treatment with E2; rather, its interaction with Grb2 in the
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cytoplasm would prevent PNRC2 binding to DCP1a, and this would consequently
suppress XRN1 recruitment and miRNA degradation.
Attempts to co-immunoprecipate PNRC2 and DCP1a with E2 treatment
have been unsuccessful, so the present study could not confirm the interaction
between these two proteins. However, PNRC2 and DCP1a interaction has been
previously reported using a yeast two-hybrid assay (Lai et al., 2012, Structure).
Similarly, PNRC2 interaction with nuclear receptors has also been reported using
a yeast two-hybrid assay system (Zhou and Chen, 2001, Nucleic Acids
Research). Other studies have overexpressed PNRC2 and nuclear receptor
levels before successfully conducting immunoprecipitation experiments (Cho et
al., 2015, PNAS). Therefore, it could be the case that the low, endogenous
expression of PNRC2 made it difficult to detect in previous Co-IP experiments.
Crosslinking of intracellular proteins with DSP (dithiobis succinimidyl propionate)
did not improve efforts to immunoprecipitate PNRC2 and DCP1a, suggesting that
the protein:protein interactions could be indirect or transient.
Moreover, it is crucial to note that altered PNRC2 signaling alone would
not account for the miRNA specific effect of E2 since decreased activation of the
degradation machinery would stabilize miRNAs in a global manner. This
suggests that PNRC2 signaling is only one aspect of the mechanism of E2mediated miRNA stabilization. It can be proposed then that the disruption of
PNRC2-DCP1a association and mRNA target upregulation have an additive
effect in the E2-mediated stabilization of miR-181a. It could be the case that
transcriptional regulation of mRNA targets by E2 determines the miRNA specific
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effect of stabilization or destabilization, while PNRC2 signaling either potentiates
or negates the overall effect.
However, as previously described, PNRC2 has diverse roles in
intracellular signaling. Not only can it bind and activate DCP1a, it can suppress
the MAPK signaling pathway by binding to Grb2 (Zhou et al., 2004, Oncogene).
Additionally, PNRC2 has been shown to be relatively promiscuous in its ability to
bind many different types of nuclear receptors. Recently, PNRC2 was shown to
bind the glucocorticoid receptor (GR) to post-transcriptionally regulate mRNA
degradation (Cho et al., 2015, PNAS). Therefore, knocking down PNRC2
expression could have resulted in unanticipated downstream signaling events.
Upon further investigation of PNRC2’s role in miRNA stabilization, it would be
imperative to consider how differences in the cellular environment could diminish
or potentiate PNRC2’s role in miRNA stabilization as E2 is likely not the only
stimulus that alters its overall effect.
In conclusion, the present findings support the hypothesis that estrogenmediated stabilization of miR-181a will be abolished upon knockdown of PNRC2.
These findings suggest an importance of the PNRC2 signaling pathway in
mediating the stabilizing effect of E2 on mature miR-181a levels.
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Figure 14. Proposed mechanisms of E2-mediated miRNA stabilization

CHAPTER FIVE
CONCLUSIONS AND FUTURE DIRECTIONS
The primary goal of this project was to determine how E2 altered the
expression of specific miRNAs in the rat brain. To that end, it was found that E2

increased miR-181a levels in a rat hypothalamic cell line, and this increase was
due to E2 stabilizing the mature miR-181a transcript. Furthermore, the E2mediated stabilization of miR-181a was found to be dependent on the
endogenous pool of RNA as well as PNRC2 expression.
The E2-mediated stabilization of miR-181a could potentially have
adverse consequences which lead to disease. For example, it has been
previously shown in the literature that E2 can promote metastasis in breast
cancer cells (Zheng et al., 2011, PLOS). Additionally, dysregulation of the TGF-ß
signaling pathway has also been studied extensively in breast cancer
progression and metastasis as it seems to have a dual role in either suppressing
or initiating pro-oncogenic effects (Sato et al., 2014, Breast Cancer Research).
Interestingly, one of the ways in which TGF- ß can promote breast cancer
metastasis is to upregulate miR-181a levels (Taylor et al., 2013, JCI). Activation
of TGF- ß receptors leads to the phosphorylation and subsequent activation of RSMAD 2/3 which can translocate into the nucleus to function as a transcription
factor to initiate the transcription of miR-181a. Additionally, the R-SMAD 2/3
dimer can also interact with the Drosha: DGCR complex to promote maturation of
56
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the pri-miRNA to the precursor form, which gives rise to the possibility of the
increased efficiency of miR-181a production (Hata and Davis, 2009, Cytokine
and Growth Factor Reviews). Therefore, one way in which E2 could be
promoting metastasis is by allowing for the pro-oncogenic miR-181a to exert its
effects for a longer period of time by mirroring, or perhaps exacerbating, the
effects of TGF- ß mediated miR-181a upregulation.
In the context of the brain, prolonged miR-181a activity due to
stabilization could have similarly detrimental effects. miR-181a was found to be
enriched in the neuronal synapses of rat primary cortical and hippocampal
neurons, and its overexpression decreased GluA2 levels, which is a component
of AMPARs. The miR-181a-induced reduction of GluA2 ultimately led to
decreased dendritic spine formation (Saba et al., 2011, Mol. Cell. Biol.).
Therefore, E2-mediated stabilization of miR-181a could negatively regulate
synaptic plasticity and neurotransmission in the brain.
One limitation of the present research was that it did not investigate the
effect of E2 on miRNA degradation in other tissues. Previous research has
indicated that E2 can initiate tissue-specific signaling cascades with markedly
different cellular responses (Cui et al., 2013, Trends in Molecular Medicine).
Therefore, the E2-mediation stabilization of miR-181a that was observed in a rat
hypothalamic cell line might not be present in cell lines derived from other tissues.
Similarly, in vitro studies using IVB cells do not consider the role of glial cells
such as astrocytes and microglia in mediating the effects of E2. Therefore,
further research with various tissue types is required to determine if the observed
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effect of stabilization is specific to the brain and if this effect is also seen in an in
vivo system.
Another limitation of the present research was that it was not able to
distinguish which class of RNAs was important in the E2-mediated stabilization of
miR-181a. While target-mediated stabilization by mRNA upregulation seems to
be a likely mechanism of stabilization, follow-up miRNA degradation experiments
co-incubating radiolabeled 32PmiR-181a and a custom oligonucleotide sequence
complementary to the seed sequence would provide a more detailed
understanding of the mechanism of miR-181a stabilization.
Furthermore, it would be interesting to determine if miR-181a localization
in vitro is altered after E2 treatment. RISC, or RNA induced silencing complex, is
generally thought to shield miRNAs from nucleases present in the cytoplasm.
Therefore, when loaded onto a complex of proteins, miRNAs are thought to be
more stable. Interestingly, key components of RISC, such as the Argonaute
protein family, have been reported to localize in p-bodies and other RNPs (Sen et
al., 2005, Nat Cell Bio). It has also been suggested that miRNA-induced
translational repression is achieved upon the delivery of mRNAs to these pbodies (Liu et al., 2005, Nat Cell Biol). Therefore, if miRNAs are localized to pbodies after E2 treatment, this could be one mode of stabilization. This would
represent a novel mechanism of miRNA stability that would not necessarily
include a miRNA-to-mRNA interaction or some other enzymatic process. Such a
finding would be of importance, because it would show that miRNA stability can
be affected simply by changing its localization to different foci within the cell.

59

In conclusion, E2 was found to alter the expression of specific miRNAs—
namely miR-181a—by stabilizing the mature transcript in a manner that is
dependent on both PNRC2 and endogenous RNA. The present findings add
another layer of complexity in the study of miRNA and the development of
miRNA-specific drugs. With the knowledge that hormonal triggers can regulate
miRNA turnover, this research necessitates the development of miRNA-targeted
drugs that are sex specific. Furthermore, the elucidation of miRNA stability is
important for proper understanding of the homeostatic brain as well as the
mechanisms by which miRNA can be involved in pathological conditions. The
research presented here fills important gaps in our understanding of miRNA
biology and provides an underlying foundation for future research into hormonal
alterations of miRNA stability.

CHPATER SIX
GENERAL METHODS
in vitro Preparations
IVB cells, a neuronal cell line derived from rat hypothalamus, were grown
to 70% confluency in Dulbecco’s Modified Eagle Medium (Corning)
supplemented with 10% Fetal Bovine Serum. (IVB cells were generously
provided by Dr. John Kaskow at the University of Cincinnati, OH). After 48 hours
of incubation in media with charcoal/dextran treated FBS, cells were treated with
100 nM E2 or an equivalent volume of ethanol (vehicle) for 2 hours. Cells were
immediately lysed using a mild, Nonidet-P40 (NP40) buffer to preserve protein:
protein interactions. The lysate was then collected and protein concentration was
quantified using a BCA assay (ThermoFischer Scientific). All cells were between
passage 19 and 23.
miRNA Degradation Assay
In order to observe the degradation kinetics of miR-181a and miR-124,
synthetic oligonucleotide constructs were created (Integrated DNA Technologies)
with the exact sequence of the mature strand (miR181a:
AACAUUCAACGCUGUCGGUGAGU; miR-124:
UAAGGCACGCGGUGAAUGCC). These single stranded oligonucleotide
sequences were then radiolabeled on the 5’ end using [γ32P] ATP (3000
Ci/mmmol). 10 fmols of the newly radiolabeled sequence were then incubated
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with 20 µg of protein from the lysate prepared above. Incubation of radiolabeled
constructs with the lysate was stopped at 5 different time points with formamide
loading buffer: T0, 15 minutes, 1 hour, 2 hours, and 4 hours. The resulting
mixture was then separated by electrophoresis on an 8% urea gel. Finally, the
gel was visualized by phosphorimaging to detect levels of the radiolabeled miRNA at the various time points.
Micrococcal Nuclease Treatment
1µl of MNase with a 2 x 106 gel units/ml concentration was added to 100
µg of lysate. The reaction was stopped after 30 minutes by adding excess EGTA
to a final concentration of 10mM. After MNase treatment, the miRNA degradation
assay was performed as described above.
Immunostaining for PNRC2 and DCP1a
IVB cells, grown on glass coverslips, were treated with E2 or vehicle
treatment as described above. Upon 70% confluency, the cells were fixed by
incubating with 100% methanol for 5 minutes. Following fixation, 0.25% Triton X100 was applied to permeabilize the samples. The cells were then incubated with
1% BSA in PBST (PBS + 0.1% Tween 20) for 30 minutes to prevent nonspecific
binding. Next, the sample was simultaneously incubated with a PNRC2 antibody
raised in goat (Santa Cruz) and a DCP1a antibody raised in rabbit (Sigma)
overnight at 4°C. After washing with PBS, the cells were then incubated with the
mixture of an anti-rabbit secondary antibody conjugated to Texas Red and an
anti-goat secondary antibody conjugated to FITC for 30 minutes at room
temperature. The glass coverslips containing the IVB cells were mounted on a

62

slide to be visualized by deconvolution microscopy. 15 representative pictures
were taken from each treatment group, and the images were analyzed using
IMARIS software to determine subcellular localization.
IMARIS Analysis
In order to analyze PNRC2 puncta localization relative to the nucleus, a
masked surface was created around the DAPI signal using IMARIS. This mask
was then used to create two separate channels displaying PNRC2 puncta within
the masked surface and outside the masked surface. The number of PNRC2
puncta in each channel was then determined by applying an algorithm based
upon fluorescence intensity, sphericity, and volume.
Co-localization analysis was performed by analyzing the fluorescence
intensity of both the PNRC2 and DCP1a surfaces. A threshold value of 420 was
set for the DCP1a fluorescence intensity as this was the minimum limit in which
the red (Texas Red) signal began to overlap with the green (FITC) PNRC2
signal.
DRB Treatment
IVB cells were treated with 5,6-dichlorobenzimidazole 1-β-Dribofuranoside (DRB) at a final concentration of 65 µM for 2 hours in order to
inhibit transcription. DRB was diluted in dimethyl sulfoxide at a stock
concentration of 65 mM prior to addition to cell culture media.
PNRC2 siRNA Transfection
PNRC2-siRNA (OriGene) was transfected into IVB cells at 70%
confluency to a final concentration of 10 nM. Transfection was achieved using a
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3:1 ratio of Continuum transfection reagent (Gemini) with the siRNA for 48 hours.
Scrambled siRNA (OriGene) was used as a control in all experiments to
determine whether there was any nonspecific knockdown of PNRC2 from the
duplex due to transfection alone.
Real-Time Quantitative PCR
Total RNA was isolated from samples using TRIzol reagent (Thermo). 2.5
µg of RNA was then used for poly-A tailing and cDNA synthesis (NCode). RTqPCR was performed using a miR-181a primer along with a 5sRNA primer as a
reference gene (IDT).
Statistics
Two-way ANOVA was performed to determine the interaction of time and
treatment on miRNA expression in the miRNA degradation assays. Two sample
t-tests were performed for all other experiments to determine differences
between treated and untreated groups. A p-value of less than 0.05 was
considered statistically significant.
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